Ignite Creation Date:
2025-12-24 @ 11:17 PM
Ignite Modification Date:
2026-03-06 @ 1:17 PM
Study NCT ID:
NCT01843556
Status:
COMPLETED
Last Update Posted:
2023-06-18
First Post:
2013-04-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals in Japanese Healthy Elderly Males
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077265', 'term': 'Donepezil'}], 'ancestors': [{'id': 'D007189', 'term': 'Indans'}, {'id': 'D007192', 'term': 'Indenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D010880', 'term': 'Piperidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 48}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2012-12'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-02', 'completionDateStruct': {'date': '2013-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-06-16', 'studyFirstSubmitDate': '2013-04-25', 'studyFirstSubmitQcDate': '2013-04-29', 'lastUpdatePostDateStruct': {'date': '2023-06-18', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2013-04-30', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-04', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number and frequency of adverse events', 'timeFrame': '168 hours after the end of application'}], 'secondaryOutcomes': [{'measure': 'Maximal Drug Concentration (CMax)', 'timeFrame': '216 hours after the end of application'}, {'measure': 'Area Under the Plasma Concentration-Time Curve (AUC)', 'timeFrame': '216 hours after the end of application'}, {'measure': 'Time to Reach Maximum Observed Plasma Concentration (Tmax)', 'timeFrame': '216 hours after the end of application'}, {'measure': 'Plasma Decay Half-Life (t1/2)', 'timeFrame': '216 hours after the end of application'}]}, 'conditionsModule': {'conditions': ['Healthy Elderly Male']}, 'descriptionModule': {'briefSummary': 'A phase 1 study of E2022 tape formulation in healthy elderly males to evaluate the safety and pharmacokinetics.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['OLDER_ADULT'], 'minimumAge': '65 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion criteria:\n\n1. Male non-smokers (not smoking at least 4 weeks before Period 1) aged 65 years or older at informed consent\n2. BMI at screening is 18.5 kg/m2 or above - below 28.0 kg/m2\n3. Written informed consent\n4. Given full explanation of this study and is willing to and able to comply with the protocol requirements\n\nExclusion criteria:\n\n1. Have a current or past history of disorder requiring medical treatment within 8 weeks before the first application or infection within 4 weeks before the first application\n2. Have a disorder within 4 weeks before the first application which affects the evaluation of study drug such as psychiatric, gastrointestinal, hepatic, renal, respiratory, endocrinological, hematological, neurological or cardiovascular system, or congenital metabolic abnormality\n3. Have a history of gastrointestinal surgery (e.g., liver, kidney, digestive tract) which affects the pharmacokinetics of study drug,\n4. Have a history of treatment-requiring drug or food allergy or seasonal allergy at screening\n5. Had caffeine-containing food or drink or alcohol within 72 hours before study drug application in Period I\n6. Had nutritional supplements, herbal preparations (including oriental medicines) or others (e.g., grapefruit-containing food or beverage) which may affect drug metabolizing enzymes and transporters, within 1 weeks before Period I\n7. Have used liquid products (including cosmetics) on study application sites (back, upper limb, chest), patch, tape or bandage, within 4 weeks before Period 1\n8. Present or past clinical signs of skin hypersensitivity to topical product or atopic dermatitis\n9. Excessively hairy or have shaved at application sites (back, upper limb, chest) within 4 weeks before Period 1\n10. Eczema, dermatitis, abnormal pigmentation, injury, or scar at application sites which may affect the evaluation of skin symptoms'}, 'identificationModule': {'nctId': 'NCT01843556', 'briefTitle': 'A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals in Japanese Healthy Elderly Males', 'organization': {'class': 'INDUSTRY', 'fullName': 'Eisai Inc.'}, 'officialTitle': 'A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals', 'orgStudyIdInfo': {'id': 'E2022-J081-003'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'E2022 Tape Formulation', 'interventionNames': ['Drug: E2022 Tape Formulation']}], 'interventions': [{'name': 'E2022 Tape Formulation', 'type': 'DRUG', 'otherNames': ['Donepezil'], 'description': 'E2022 tape formulation applied to different application sites and at different intervals in Japanese healthy elderly males', 'armGroupLabels': ['E2022 Tape Formulation']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Kagoshima', 'country': 'Japan', 'geoPoint': {'lat': 31.56667, 'lon': 130.55}}], 'overallOfficials': [{'name': 'Hidetaka Hiramatsu', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Eisai Co., Ltd.'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Eisai Co., Ltd.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}